AYAyşe Tekin Yılmaz

Ayşe Tekin Yılmaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayşe Tekin Yılmaz has a total of 161 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pediatric invasive meningococcal disease in Türkiye during the post-pandemic period: increased reported cases and predominance of serogroup B and severity determined by a clinical form in a multicenter hospital-based cohort

    by Esra Cakmak Taskin, Gul Arga, Basak Ceren Arslan, Isil Ezel Taskin Karacay, Mustafa Genceli, Emine Hafize Erdeniz, Ozge Kaba, Gulhadiye Avcu, Sevgi Kus, Meryem Cagla Abaci Capar, et al.

    Invasive meningococcal disease (IMD) remains a major cause of morbidity and mortality in children. Post-pandemic epidemiological patterns of pediatric IMD are not well defined in Türkiye. This study aimed to evaluate the epidemiology, clinical characteristics, outcomes, and serogroup distribution of pediatric IMD in a large multicenter cohort in Türkiye, comparing the during-COVID and post-COVID periods. This retrospective multicenter hospital-based study included children aged 1 month–18 years hospitalized with laboratory-confirmed IMD in 39 hospitals across 23 provinces. Cases were grouped as during-COVID (January 2020–May 2022) and post-COVID (June 2022–December 2025). A total of 166 patients (median age 25 months; 59.6% male) were included; 25 occurred during-COVID and 141 post-COVID. The number of reported cases in participating centers increased after 2022, with seasonal peaks in winter and early spring. Children under 5 years accounted for 62.7% of cases, and infants (< 1 year) were the largest single age group overall (38.6%). The proportion of children under 5 years was lower in the post-COVID period (58.9% vs 84.0%; OR 0.27, 95% CI 0.09–0.84), indicating a relative shift toward older age groups rather than a reduction in disease burden among infants. Pediatric intensive care admission occurred in 69.9% of cases, and overall mortality was 13.3%. Mortality varied markedly by clinical form, from 1.2% in meningitis alone to 21.7% in combined meningitis and meningococcemia and 38.1% in meningococcemia alone (p < 0.001). Only 2.4% of children had received any meningococcal vaccine before their illness. Serogroup data were available for 60.8% of patients, with grouping coverage differing between periods (32.0% vs 66.0%). Among cases with available serogroup data, serogroup B accounted for 69.9% in the post-COVID period and for half of the eight grouped cases during the pandemic. In unadjusted exploratory analysis restricted to cases with serogroup data, mortality was higher in serogroup B than non-B infections (21.7% vs 3.1%; OR 8.61, 95% CI 1.08–68.8); in an exploratory model adjusting for clinical form, age, and period, with ungrouped cases retained as a separate category, serogroup B remained associated with mortality (aOR 7.59, 95% CI 1.55–75.65). Conclusion: In this multicenter hospital-based cohort, reported pediatric IMD cases increased in the post-pandemic period, with a persistent burden in infants, a relative shift toward older age groups, and predominance of serogroup B among grouped cases. These findings highlight the importance of strengthened surveillance and support further evaluation of meningococcal vaccination strategies, including MenB vaccination. What is Known: • Invasive meningococcal disease remains a severe pediatric infection with high morbidity and mortality, despite treatment. • The COVID-19 pandemic and the subsequent easing of restrictions altered IMD epidemiology globally. What is New: • Reported pediatric IMD cases increased in the post-pandemic period, with a relative shift toward older children while the proportion of infants remained unchanged (38.3% vs 40.0%); serogroup B predominated among cases with an available serogroup result, although differential availability of these data precludes conclusions about change over time. • Mortality was determined principally by clinical form, ranging from 1.2% in meningitis alone to 38.1% in meningococcemia alone, and only 2.4% of children had received any meningococcal vaccine before their illness.

  • Clinical characteristics and predictors of severe pertussis in hospitalized children after the COVID-19 period in Türkiye: a multicenter study

    by Sevliya Ocal-Demir, Pınar Canizci Erdemli, Esra Cakmak Taskin, Ayşe Tekin Yilmaz, Semra Bayturan Şen, Deniz Ergün, Hincal Ozbakir, Berna Çetin Kahraman, Canan Özlü, Berker Okay, et al.

    Pertussis resurged globally, after the relaxation of COVID-19 measures, underscoring its continued relevance as a public health concern, yet data remain li


  • Çocukluk Çağı Rutin Aşı Takvimi ve Bağışıklama Uygulamaları

    by Ayşe Tekin Yılmaz

    Aşı enfeksiyon hastalıklarından korunmanın etkin ve güvenli aynı zamanda da en kolay yollarından biridir. Her gün farklı hastalıklarının tanımlandığı, yeni tedavi yöntemlerine bir yenisinin eklendiği modern tıbbın en parlak dönemlerinden birinin yaşandığı günümüze enfeksiyon hastalıklarının önlenmesinde halen temiz su kaynaklarının sağlanması dışında en etkili yöntem aşı uygulamalarıdır. Aşı uygulamaları aynı zamanda koruyucu sağlık hizmetleri içinde de önemli bir yer tutmaktadır. Aşı sadece bireysel koruma sağlamakla kalmaz toplum genelinde aşı uygulaması belirli oranların üzerine çıkartılabildiğinde toplumsal bağışıklığın da oluşmasını sağlar. Toplumsal bağışıklık sağlanmasından bir sonraki adım ise herhangi bir mikroorganizmanın eradike edilmesi yani neden olduğu hastalığın ortadan kalkmasıdır. Bu yazıda ülkemizde sağlık bakanlığı tarafınca önerilen ve uygulanan çocukluk çağı aşı programında yer alan aşılardan, uygulama özelliklerinden ve uygulama öncesinde ya da sonrasında dikkat edilmesi gereken durumlardan bahsedilecektir.


  • Çocukluk Çağı Ateş Yönetimi Değerlendirmesi

    by Taylan Çelik, Kamile Ötiken Arıkan, Emin Sami Arısoy, Burcu Bursal, Emine Hafize Erdeniz, Mustafa Hacımustafaoğlu, Manolya Kara, Hatice Karaoğlu, Sevliya Öcal Demir, Canan Özlü, et al.

  • Evaluation of Childhood Fever Management

    by Taylan Çelik, Kamile Ötüken Arıkan, Emin Sami Arısoy, Burcu Bursal, Emine Hafize Erdeniz, Mustafa Hacımustafaoğlu, Manolya Kara, Hatice Karaoğlu, Sevliya Öcal Demir, Canan Özlü, et al.


  • Active and Latent Tuberculosis in Children Treated with Anti-TNF-α: A Retrospective Multicenter Study

    by Nazan Dalgic, Ayse Sahin, Selda Hancerli Torun, Ozge Kaba, Pinar Onal, Ayse Tekin Yilmaz, Ozden Turel, Belma Yasar, Manolya Kara, Deniz Aygun, et al.

    Objective This study aimed to investigate the frequency of latent and active tuberculosis (TB) in pediatric patients receiving anti-tumor necrosis factor (TNF)-α therapy. Methods Patients younger than 18 years with various inflammatory diseases and treated with anti-TNF-α agents in the past five years were included in the study. The patients' ages, follow-ups, medications received, clinical and laboratory findings, and treatments applied were recorded retrospectively. Results Of the 160 patients included in the study, 78 (48.8%) were girls. The mean age was 139.54 ± 48.74 (30–226) months. Sixty (37.5%) patients had inflammatory eye disease, 55 (34.4%) had rheumatologic and autoimmune disease, and 45 (28.1%) had inflammatory bowel disease. As anti-TNF-α treatment, 67 (41.9%) patients received adalimumab, 50 (31.2%) received infliximab, and 43 (26.9%) received etanercept. As a result of TB screening performed prior to the treatment, 44 (25.4%) patients were started on isoniazid treatment with the diagnosis of latent TB. During follow-up, latent TB infection was detected in 16 (9.2%) patients and isoniazid treatment was started. The time to develop latent TB under anti-TNF-α treatment ranged from 3 to 28 months. During the treatment, active TB infection developed in two (1.2%) patients and anti-TB treatment was initiated. Conclusion It is of vital importance to evaluate patients receiving, or planned to receive, anti-TNF-α treatment, for TB infection and to initiate appropriate treatments if latent or active TB infection is identified.